Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: Compugen Names CEO of US Subsidiary

This story has been updated from a previous version.

NEW YORK, March 28 – Compugen has appointed Vincent Zurawski, Jr, as CEO of its US operations, a new position based at the company’s Jamesburg, NJ, headquarters, the company said Wednesday. 

Zurawski, formerly director of research business development at the University of Pennsylvania School of Medicine and Health System, will direct Compugen’s US subsidiary, help develop the overall business strategy for Compugen, and manage the business and product development of the company’s drug discovery efforts, said Tsipi Haitovsky, a Compugen spokeswoman.

Prior to working at Penn, Zurawski helped found two biotechnology companies, Centocor, a manufacturer of monoclonal antibodies recently purchased by Johnson and Johnson, and Appollon, a developer of DNA vaccines.  

Zurawski’s appointment serves to complement the current management, whose skills are mathematically-intensive, with skills in biology, said Haitovsky. “We’re bringing in someone with Zurawski’s profile because of his extensive experience on the business side, and also because he brings experience in biology,” she said. “We have [managers with] biology experience already, but not enough.”

In addition to the company’s New Jersey facility, where the company’s US management and product development efforts are located, Compugen opened a sales and marketing office last December in Sunnyvale, Calif. Haitovsky added that the recent emphasis on the US market reflects the location of most of Compugen’s customers.

In February, Compugen announced it would launch a new proteomics service called Protocall in the first and second quarters of 2001 that would allow customers to match protein samples with the company’s database of 160,000 proteins. The service will be accessible through Compugen’s LabOnWeb service.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.